Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs
Alcoholism is a serious public health problem throughout the world. Current pharmacotherapies for the treatment of this disorder are poorly effective. Preclinical and clinical findings point to nicotinic acetylcholine receptors (nAChRs) as a promising target for the development of novel and effective medications. Assuage Pharmaceuticals, in collaboration with Torrey Pines Institute for Molecular Studies, has discovered a new class of potent and selective α4β2 nAChR antagonists.
Here, it was hypothesized that α4β2 nAChR antagonism is a viable approach for treatment of alcohol use disorders.
When tested in rats, one lead compound, AP-202, attenuated both operant alcohol and nicotine self-administration in a paradigm in which the two reinforcers were concurrently available. The conotoxin TP2212-59, a selective α3β4 nAChR antagonist, was only effective in reducing nicotine self-administration. AP-202 also reduced alcohol but not food responding when alcohol was presented as the only reinforcer, whereas the commercially available α4β2 nAChR antagonist dihydro-β-erythroidine failed to alter alcohol self-administration. AP-202 did not block relapse-like behavior induced by previously alcohol-associated stimuli or yohimbine stress. In a reinstatement paradigm, in which alcohol seeking was triggered by a nicotine challenge, a behavior successfully inhibited by the nonselective nAChR antagonist mecamylamine, AP-202 was not effective, while pretreatment with TP2212-59 abolished nicotine-induced reinstatement of alcohol seeking.
These findings suggest differential roles for α4β2 and α3β4 nAChR on alcohol taking and seeking with selective blockade of α4β2 nAChR being more implicated in modulating alcohol taking while selective blockade of α3β4 nAChR is involved in nicotine-induced alcohol seeking.
KeywordsAlcohol Nicotine α4β2 nAChRs α3β4 nAChRs Self-administration Reinstatement
We are thankful to Shannon Ortiz-Umpierre and Roman Ramirez for animal care and Ginamarie Debevec for support in analytical chemistry.
This work was supported by NIH grants R41 AA025298 and R44 DA036968.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Ayanwuyi LO, Carvajal F, Lerma-Cabrera JM, Domi E, Bjork K, Ubaldi M, Heilig M, Roberto M, Ciccocioppo R, Cippitelli A (2013) Role of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of marchigian sardinian alcohol-preferring rats. Frontiers Psychiatr 4:23CrossRefGoogle Scholar
- Carroll FI, Lee JR, Navarro HA, Ma W, Brieaddy LE, Abraham P, Damaj MI, Martin BR (2002) Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′,3′-disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes: epibatidine analogues. J Med Chem 45:4755–4761CrossRefPubMedGoogle Scholar
- Carroll FI, Ware R, Brieaddy LE, Navarro HA, Damaj MI, Martin BR (2004) Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2′-fluoro-3′-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist. J Med Chem 47:4588–4594CrossRefPubMedGoogle Scholar
- CDC (2014) Centers for Desease Control & Prevention. Alcohol-related disease impact (ARDI) application (2006–2010)Google Scholar
- Chang YP, Banerjee J, Dowell C, Wu J, Gyanda R, Houghten RA, Toll L, McIntosh JM, Armishaw CJ (2014) Discovery of a potent and selective alpha3beta4 nicotinic acetylcholine receptor antagonist from an alpha-conotoxin synthetic combinatorial library. J Med Chem 57:3511–3521CrossRefPubMedPubMedCentralGoogle Scholar
- Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, Shaffer CL, Lowe J, Rollema H, Bartlett SE (2011) Partial agonists of the alpha3beta4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 36:603–615CrossRefPubMedGoogle Scholar
- Cippitelli A, Damadzic R, Singley E, Thorsell A, Ciccocioppo R, Eskay RL, Heilig M (2012) Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. Pharmacol Biochem Behav 100:522–529CrossRefPubMedGoogle Scholar
- Cippitelli A, Wu J, Gaiolini KA, Mercatelli D, Schoch J, Gorman M, Ramirez A, Ciccocioppo R, Khroyan TV, Yasuda D, Zaveri NT, Pascual C, Xie XS, Toll L (2015b) AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol 172:1834–1845CrossRefPubMedPubMedCentralGoogle Scholar
- Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63CrossRefPubMedGoogle Scholar
- Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, Picciotto MR, Changeux JP, Collins AC (1999) Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. J Pharmacol Exp Ther 289:1090–1103PubMedGoogle Scholar
- NHTSA (2016) National Highway Traffic Safety Administration. 2015 motor vehicle crashes: OverviewGoogle Scholar
- Rezvani AH, Slade S, Wells C, Petro A, Lumeng L, Li TK, Xiao Y, Brown ML, Paige MA, McDowell BE, Rose JE, Kellar KJ, Levin ED (2010) Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology 211:161–174CrossRefPubMedPubMedCentralGoogle Scholar
- Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985–994CrossRefPubMedGoogle Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA) (2013) National Survey on Drug Use and Health (NSDUH). Table 5.8B—Substance Dependence or Abuse in the Past Year among Persons Aged 18 or Older, by Demographic Characteristics: Percentages, 2012 and 2013. Available at: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabsPDFWHTML2013/Web/HTML/NSDUH-DetTabsSect5peTabs1to56-2013.htm#tab5.8b
- Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello MR, Leslie FM (2012) AT-1001: a high affinity and selective alpha3beta4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology 37:1367–1376CrossRefPubMedPubMedCentralGoogle Scholar
- Wouda JA, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D, Schoffelmeer AN, Pattij T, De Vries TJ (2011) Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology 216:267–277CrossRefPubMedPubMedCentralGoogle Scholar
- Wu J, Zhang Y, Maida LE, Santos RG, Welmaker GS, LaVoi TM, Nefzi A, Yu Y, Houghten RA, Toll L, Giulianotti MA (2013) Scaffold ranking and positional scanning utilized in the discovery of nAChR-selective compounds suitable for optimization studies. J Med Chem 56:10103–10117CrossRefPubMedPubMedCentralGoogle Scholar
- Wu J, Cippitelli A, Zhang Y, Debevec G, Schoch J, Ozawa A, Yu Y, Liu H, Chen W, Houghten RA, Welmaker GS, Giulianotti MA, Toll L (2017) Highly selective and potent alpha4beta2 nAChR antagonist inhibits nicotine self-administration and reinstatement in rats. J Med Chem 60:10092–10104CrossRefPubMedGoogle Scholar
- Zhao-Shea R, DeGroot SR, Liu L, Vallaster M, Pang X, Su Q, Gao G, Rando OJ, Martin GE, George O, Gardner PD, Tapper AR (2015) Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Nat Commun 6:6770CrossRefPubMedPubMedCentralGoogle Scholar